Hints and tips:
...Acalabrutinib was inherited by Merck when it bought Schering-Plough in 2009 but it later disposed of the drug....
...Ms Jung, who was chief executive from 2001 until April, will be replaced as chairman by Fred Hassan, a current board member and former chief executive of Schering-Plough, the pharmaceutical group that merged...
...In 2009, the Securities and Exchange Commission subpoenaed several hedge funds seeking documents relating to the patent expiration-fuelled takeover boom of 2009 when Schering Plough combined with Merck and...
...In July Merck announced that it was cutting up to 13,000 jobs as it looked to realise the cost savings promised when it acquired Schering Plough, the pharmaceutical company, for $41bn in 2009....
...The Genentech deal, combined with the “megamergers” in the same year of Pfizer’s $68bn purchase of Wyeth and Merck’s of Schering-Plough for $41bn, was a recent high water mark in dealmaking in the healthcare...
...It continues to project $3.5bn in synergies from the Schering acquisition....
...that they had abandoned plans to reintegrate their Merial partnership, initially created in 1997 and set to be reconstituted on a larger scale following a restructuring triggered by Merck’s purchase of Schering-Plough...
...buy-backs and dividend increases as well as unveiling plans to appoint to its board Jean-Pierre Garnier, the former head of GlaxoSmithKline, and Robert Bertolini, the former chief financial officer of Schering-Plough...
...In a deal that ends an arbitration triggered by Merck’s $41bn takeover of Schering-Plough in 2009, the company has scaled back its control over Remicade and Simponi, the reformulated self-injected version...
...In a deal that ends arbitration triggered by Merck’s $41bn takeover of Schering-Plough in 2009, the company has scaled back its control over Remicade and Simponi, the reformulated self-injected version....
...pharmaceutical companies, which had jointly run Merial since 1997, and announced their intention in March last year to recombine their assets to include products acquired by Merck after its acquisition of Schering-Plough...
...Jeff Stute, currently co-head of North American M&A, will become head of the North America healthcare group, while Robbie Huffines, who advised Merck on its acquisition of Schering Plough and is working...
...It signals the biggest takeover in the pharmaceutical sector since 2009, when Sanofi-Aventis and several of its larger peers were left behind by the large-scale takeovers of Wyeth by Pfizer, Schering-Plough...
...Mr Clark, who took charge in 2005, adopted a relatively low public profile while overseeing changes including the $49bn takeover last year of Schering-Plough; an expansion of partnerships and alliances with...
...In the US, Merck has announced plans to cut 15 per cent of the workforce, or 15,000 jobs, by 2012 in restructuring after buying Schering-Plough....
...The $1m penalty ties with a 2003 settlement by Schering-Plough as the biggest levied by the SEC for a Regulation FD violation since the rules were imposed in 2000....
...FT Alphaville notes shares were trading 33 per cent higher on Wednesday as expectations that a possible counterbid could emerge from either US drug company Merck or consumer goods firm Schering Plough, also...
...As they note (emphasis ours): Merck owns the Scholl brand in the US, and Schering Plough recently said it is looking to expand into HPC, so these are towards the top of possible counterbidders....
...The deal follows an agreement last year under which Sanofi-Aventis bought out Merial from Merck, after Merck purchased Schering-Plough for $41bn in 2009 and acquired the Intervet/Schering-Plough animal health...
...Cliffs Natural Resources pulled back 7.5 per cent to $54.55, Vulcan Materials was 5.8 per cent lower at $55.50, while Titanium Metals Corp fell 6.5 per cent to $14.49....
...Merck reported net income down 77 per cent to $330m according to US accounting standards after taking accounting of one-off costs related to its purchase of Schering-Plough which almost doubled sales to...
...Chris Viehbacher, chief executive of the French pharmaceutical group, confirmed as “highly probable” the option to combine its subsidiary Merial with the Intervet and Schering-Plough businesses now controlled...
...next year on whether to make fresh investments to combine Meriel – the animal health joint venture it runs with Merck of the US – with the extra products Merck has acquired in its recent take-over of Schering-Plough...
...expenditure and closed some disease-research units in the past few months, partly to reduce duplication following a series of large-scale acquisitions such as Pfizer’s takeover of Wyeth and Merck’s of Schering-Plough...
...The deal will combine the French drugmaker’s Merial unit and Merck’s Intervet/Schering Plough division. Sanofi shares added 0.8 per cent to €56.17....
International Edition